Gesynta Pharma AB Secures $29M Series B Funding for Groundbreaking Endometriosis Treatment Development

Gesynta Pharma AB is thrilled to announce the successful completion of a funding round, raising an impressive $29 million to advance its innovative drug development initiatives.

With a sharp focus on addressing unmet medical needs in the realm of inflammatory diseases, Gesynta Pharma is advancing its lead drug candidate, vipoglanstat (GS-248), which is currently in clinical phase II trials for treating endometriosis—an agonizing condition that plagues approximately 10 percent of women of reproductive age.

With current treatment options largely inadequate, this funding will bolster Gesynta's efforts to harness the therapeutic potential of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition, offering hope for significant improvements in patient outcomes.

In addition to vipoglanstat, this round will also support the clinical phase I development of Gesynta’s second drug candidate, GS-073, which shares the same mechanism of action and targets chronic inflammatory pain.

This promising pipeline is grounded in cutting-edge research from the esteemed Karolinska Institutet, and the company is proud to be backed by major shareholders including Industrifonden, Hadean Ventures, and Linc, along with a network of successful life science entrepreneurs.

The newly secured funds will facilitate the acceleration of clinical trials and enhance research efforts, bringing Gesynta one step closer to revolutionizing treatment options for patients suffering from debilitating chronic inflammatory conditions.

This milestone underscores our commitment to transforming lives through innovative science and patient-centered drug development.